Clinical Analysis On Intravitreal Injection Of Conbercept In The Treatment Of Macular Edema Secondary To Retinal Vein Occlusion

Objective Treatment of macular edema secondary to retinal vein occlusion with intravitreal injection of anti-vascular endothelial growth factor(VEGF)was the latest treatment for this disease.Conbercept was a new generation of anti-VEGF drugs with multiple targets,strong affinity,long acting time and other advantages.This study was to explore the clinical efficacy and safety of intravitreal injection of conbercept in the treatment of macular edema secondary to retinal vein occlusion and to provide reference for clinical application of conbercept.Methods The prospective study was carried out in 21 patients(21 eyes)that received intravitreal injection of conbercept in the treatment of macular edema secondary to retinal vein occlusion.All patients underwent a complete eye examination including the best-corrected visual acuity(BCVA)according to the Early Treatment of Diabetic Retinopathy(ETDRS)protocol,slit lamp biomicroscopy,intraocular pressure measurement,optical coherence tomography(OCT)and fundus fluorescein angiography(FFA).The BCVA and the center retinal thickness(CRT)by OCT were observed at week 1,month l,month 2,month 3,month 6,month 9 and month 12 after treatment.Comparison the BCVA and the CRT before and after treatment.At the same time,observe 12 months after treatment of endophthalmitis,uveitis,cataract progress and high intraocular pressure.Through the statistical analysis method of clinical efficacy and safety of conbercept.Results Compared the outcome measure of month 6 and month 12 after treatment with before,the mean changes of BCVA were statistically significant(P<0.05).At month 12,the number of patients who impro-ved>15 letters of BCVA was 11(52.4%);the number of patients who improved<15 letters of BCVA was 7(33.3%);the number of patients who didn't improved of BCVA was 3(14.3%).Before treatment,the CRT was 373-1593um,with the average of 615.66±267.9um;after 6 months treatment,the CRT was 218-806um,with the average of 412.3±134.5um;after 12 months treatment,the CRT was 228-823um,with the average of 341.5±137.7um.Compared the outcomemeasure of month 6 and month 12 after treatment with before treatment,the mean changes of CRT were statistically significant(P<0.05).All subjects were injected 70 times.The mean number of intravitreal injections was 3.33.There were 3 people who received five injections,there were 5 people who received four injections,there were 9 people who received three injections and there were 4 people who received two injections.The number of intravitreal injections who sufferd CRVO was 29 and the mean number was 3.63.The number of intravitreal injections who sufferd BRVO was 41 and the mean number was 3.15.Conclusion Intravitreal conbercept for macular edema secondary to retinal vein occlusion was rapid,effective and safe.Within 3 months,patients with intravitreal conbercept should be returned visit every month.After that,patients should be returned visit every 3 months.According to the need to use the principle of injection could maintain the efficacy.The average injection was 3-4 times during the first year.